Closing VRUS (Pharmasset) underperform
The retreat from unreasonable highs on phase I data appears to have slowed at a much more reasonable market cap. Small cap biotechs rarely maintain stable stock prices in the absence of positive catalysts, and Pharmasset hasn't had much to say lately. The stock will likely trade in a narrow range until more data becomes available for R7128 or clevudine. If it leaves the 16-20 range, I'll be back in to pursue my destiny as score leader.